AVLAR BIOVENTURES
Avlar was founded in 1999 by Alan Goodman and Daniel Roach and manages Avlar Fund II (£43m) and the First Cambridge Gateway Fund (£35m). Avlar has invested in eighteen companies across a range of sub-sectors of the bioscience industries. Ten are still private, two have been merged, three have been bought by public companies, two have been sold for cash and two listed on the public markets. Prior to the formation of Avlar Messrs Roach and Goodman co-founded or seed financed nine life science companies. Seven of these were listed on recognized Stock Exchanges producing highly profitable realizations. These included Acambis, Chiroscience, Core, Salix and Oxford Biomedica.
AVLAR BIOVENTURES
Industry:
Finance Financial Services Venture Capital
Founded:
1999-01-01
Status:
Closed
Contact:
44 (0) 1954 211 515
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail CPanel Microsoft DNS Zen Internet
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2010-01-20 | Crescendo Biologics | Avlar BioVentures investment in Series A - Crescendo Biologics | 7.3 M USD |
| 2009-10-12 | Crescendo Biologics | Avlar BioVentures investment in Seed Round - Crescendo Biologics | 4.5 M GBP |
| 2006-07-18 | CellCentric | Avlar BioVentures investment in Venture Round - CellCentric | 1.2 M GBP |
| 2006-07-07 | Takeda Cambridge | Avlar BioVentures investment in Series D - Takeda Cambridge | 12.96 M USD |
| 2006-01-01 | NXVISION | Avlar BioVentures investment in Venture Round - NXVISION | 688 K USD |
| 2005-08-01 | Intercytex Group | Avlar BioVentures investment in Series D - Intercytex Group | 12 M GBP |
| 2005-05-01 | Amura | Avlar BioVentures investment in Venture Round - Amura | 1.84 M USD |
| 2005-04-07 | CellCentric | Avlar BioVentures investment in Venture Round - CellCentric | 250 K GBP |
| 2005-01-07 | Takeda Cambridge | Avlar BioVentures investment in Venture Round - Takeda Cambridge | 9.38 M USD |
| 2004-12-01 | Purely Proteins Limited | Avlar BioVentures investment in Series B - Purely Proteins Limited | 3.6 M USD |